Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients

Journal of Urology

Volumn 155, Issue 1, 1996, Pages 19-25

  Hänninen, Enrique Lopez ^a   Kirchner, Hartmut ^a   Atzpodien, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carcinoma, renal cell; Fluorouracil; Interferon ; Interleukin 2; Risk factors

Indexed keywords

FLUOROURACIL; HEMOGLOBIN; LACTATE DEHYDROGENASE; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; BONE LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL PROTOCOL; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; NEUTROPHIL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HOME CARE SERVICES, HOSPITAL-BASED; HUMAN; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0029655348     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66527-3     Document Type: Article

References (25)

1. Patel, N. P. and Lavengood, R. W.: Renal cell carcinoma: natural history and results of treatment. J. Urol., 119: 722, 1978.
2. Krown, S. E.: Therapeutic options in renal cell carcinoma. Sem. Oncol., suppl. 5, 12: 13, 1985.
3. Maldazys, J. D. and deKernion, J. B.: Prognostic factors in metastatic renal carcinoma. J. Urol., 136: 376, 1986.
4. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E. and Rubin, J. T.; A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med., 316: 889, 1987.
5. West, W. H., Tauer, K. W., Yannelli, J. R., Marshall, G. D., Orr, D. W., Thurman, G. B. and Oldham, R. K.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl. J. Med., 316: 898, 1987.
6. Figlin, R. A., Belldegrun, A., Moldawer, N., Zeffren, J. and deKernion, J.: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol., 10: 414, 1992.
7. Rosenstein, M., Ettinghausen, S. E. and Rosenberg, S. A.: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol., 137: 1735, 1986.
8. Lee, R. E., Lotze, M. T., Skibber, J. M., Tucker, E., Bonow, R. O., Ognibene, F. P., Carrasquillo, J. A., Shelhamer, J. H., Parrillo, J, E. and Rosenberg, S. A.: Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol., 7: 7, 1989.
9. Atzpodien, J., Körfer, A., Franks, C. R., Poliwoda, H. and Kirchner, H.: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet, 335: 1509, 1990.
10. Atzpodien, J., Poliwoda, H. and Kirchner, H.: alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Sem. Oncol., suppl. 7, 18: 108, 1991.
11. Sleijfer, D. T., Janssen, R. A., Buter, J., de Vries, E. G., Willemse, P. H. and Mulder, N. H.: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on a outpatient basis. J. Clin. Oncol., 10: 1119, 1992.
12. Reiter, Z., Ozes, O. N., Blatt, L. M. and Taylor, M. W.: A dual anti-tumor effect of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin. Immunol. Immunopath., 62: 103, 1992.
13. Wadler, S. and Schwartz, E. L.: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50: 3473, 1990.
14. Elson, P. J., Witte, R. S. and Trump, D. L.: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res., 48: 7310, 1988.
15. De Forges, A., Rey, A., Klink, M., Ghosn, M., Kramar, A. and Droz, J. P.: Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Sem. Surg. Oncol., 4: 149, 1988.
16. Palmer, P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R. and Franks, C. R.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol., 3: 475, 1992.
17. Cox, D. R.: Regression models and life tables. J. Roy. Stat. Soc. B, 34: 187, 1972.
18. Mantel, N. and Haenzsel, W.: Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst., 22: 719, 1959.
19. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
20. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H. and White, D. E.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J.A.M.A., 271: 907, 1994.
21. Golimbu, M., Joshi, P., Sperber, A., Tessler, A., Al-Askari, S. and Morales, P.: Renal cell carcinoma: survival and prognostic factors. Urology, 27: 291, 1986.
22. Medeiros, L. J., Gelb, A. B. and Weiss, L. M.: Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer, 61: 1639, 1988.
23. Atzpodien, J., Schomburg, A., Kirchner, H. and Poliwoda, H.: Interleukin-2 and other cytokines. In: The Role of Interleukin-2 in the Treatment of Cancer Patients. Edited by J. Wagstaff. Boston: Kluwer Academic Publishers, pp. 141-167, 1993.
24. Sella, A., Logothetis, C. J., Fitz, K., Dexeus, F. H., Amato, R., Kilbourn, R. and Wallace, S.: Phase II study of interferon-α and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J. Urol., 147: 573, 1992.
25. Lopez Hänninen, E., Poliwoda, H. and Atzpodien, J.: Interferon-α/5-fluorouracil: a novel chemo/immunotherapy for metastatic renal cell carcinoma. Cancer Biother., 10: 21, 1995.